Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301620 | 0.84 | TRPM8 (0.51) | RAB9AGAAMAPTMEN1KMT2A | |
| SCHEMBL21035478 | 0.81 | MAPT (0.53) | RAB9AMAPTPRKCZPTPN11MEN1 | |
| SCHEMBL2180059 | 0.81 | ALDH1A1 (0.55) | RAB9AGAAMAPTMEN1KMT2A | |
| SCHEMBL1756208 | 0.79 | XDH (0.57) | RAB9AGAAMAPTXDHALDH1A1 | |
| SCHEMBL2822552 | 0.79 | CDC7 (0.68) | RAB9AGAAARMAPTPRKCZ | |
| SCHEMBL27908158 | 0.78 | XDH (0.56) | RAB9AGAAMAPTXDHMEN1 | |
| SCHEMBL12644425 | 0.76 | MAPT (0.48) | RAB9AGAAMAPTXDHMEN1 | |
| SCHEMBL1756326 | 0.76 | RAB9A (0.63) | RAB9AGAAARMAPTPRKCZ | |
| SCHEMBL5095729 | 0.76 | RAB9A (0.57) | RAB9AGAAARMAPTPRKCZ | |
| SCHEMBL14541793 | 0.75 | XDH (0.56) | RAB9AGAAMAPTXDHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722901-B2 | Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity | Piramal Enterprises Limited (IN) | 2014-05-13 | — | — | US | disclosed |
| EP-2496564-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | Piramal Life Sciences Limited (IN) | 2012-09-12 | — | — | EP | disclosed |
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | Piramal Enterprises Limited (IN) | 2012-08-23 | — | — | US | disclosed |
| WO-2011055289-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | DGAT1, DGAT2, DLAT | RAB9A 3809/4885GAA 118/4885AR 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.